FibroGenesis Collaborates with R4D Biotech, expands fight against COVID-19 in Brazil

▴ fibrogenesis-collaborates-r4d-biotech-expands-fight-against-covid19-through-international-collaboration-brazil
FibroGenesis signs cooperation agreement with R4D Biotech of São Paulo to advance the development of PneumoBlast cell therapy for the treatment of COVID-19

FibroGenesis, the leading developer of fibroblast-based therapeutic solutions for unmet medical needs, has signed a clinical collaboration agreement with Brazilian company R4D Biotech. FibroGenesis has the world's largest patent portfolio in the field of cell therapies with fibroblasts and is expanding its ongoing clinical programs on an international level. The partnership paves the way for clinical trials of PneumoBlast in Brazil as a unique treatment for acute lung failure in COVID-19 patients, in parallel with clinical trials in the US after approval by the FDA.

The administration of PneumoBlast in preclinical and animal studies led to a significant improvement in the immunological signalling molecules, thereby reducing the concentrations of the inflammatory cytokines interleukin-1 beta, interleukin-6, interleukin-8, interleukin-17, interleukin-18 and the tumour necrosis factor-alpha TNFa were reduced. Company scientists have also shown that PneumoBlast induced a statistically significant decrease in pulmonary fibrosis and lung scars in animals infected with COVID-19, especially when compared to more conventional bone marrow-derived mesenchymal stem cells (BMSC) treatments. In addition, recent data confirm the potential benefits of PneumoBlast in preventing blood clotting in COVID-19.

"The scientific and medical community is constantly learning about the biological and medical consequences of COVID-19 infection, and FibroGenesis is committed to contributing to the therapeutic opportunities currently being developed around the world to combat the virus," said Pete O ' Heeron , Chief Executive Officer of FibroGenesis : " Working with R4D Biotech is another strategic milestone that underscores our commitment to expanding fibroblast research worldwide."

"The laboratory results, which indicate that our cell therapy approach promotes therapeutic effects on animal models in the acute stage of COVID-19 and also a cure for the residual pathology observed in COVID-19 patients, impressed our research team," said Thomas Ichim, PhD., Chief Scientific Officer of FibroGenesis .

"Technology transfer is at the heart of this partnership," said Paulo Ferraz, head of BRICS and New Markets for the international fund Newstar Ventures and advisor to FibroGenesis on this transaction. "R4D Biotech has access to advanced resources, research facilities and hospitals and its pool of talented staff include scientific advisors who are recognized academics and distinguished members of the Brazilian Academy of Pharmaceutical Sciences. The PneumoBlast ™ clinical trial will mark the first step in a long-term partnership designed to help deliver advanced therapeutic Finding solutions to unsolved health problems.

Tags : #FibroGenesis #R4DBiotech #LatestUSFDAApprovalDtd0210 #LatestPharmaNewsDtd0210 #PauloFerraz #PeteOHeeron

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024